Candida Infection
Learn about Candida infection (Candidiasis), including thrush and yeast infection diagnosis, clinical documentation, and medical coding. Find information on healthcare provider resources for Candida albicans, treatment options, and ICD-10 codes related to yeast infections and oral thrush. This resource supports healthcare professionals in accurate diagnosis and coding for optimal patient care.
Fungal infection caused by Candida species, commonly Candida albicans.
Itching, burning, white discharge, redness, skin rash. Symptoms vary by location (mouth, skin, vagina).
Warm, moist areas. Oral thrush, diaper rash, vaginal yeast infections, skin folds.
ICD-10 Code Families
Complete code families applicable to B37.9
When to use each related code
| Description | When to use |
|---|---|
| Fungal infection caused by Candida species. | Use for infections of skin, mouth, vagina, or systemic candidiasis. Consider species if known. |
| Bacterial vaginosis, not caused by Candida. | Use for vaginal discharge with fishy odor, clue cells, not responding to antifungals. Exclude Candida. |
| Trichomonas vaginalis infection. | Use for vaginitis with frothy discharge, strawberry cervix. Test for Trichomonas. |
Best-practice checklist
- ✓Document infection site (e.g., oral, vaginal, skin)
- ✓Record symptoms (e.g., itching, discharge, pain)
- ✓Note risk factors (e.g., diabetes, antibiotics)
- ✓Describe clinical findings (e.g., white plaques, erythema)
- ✓Specify diagnostic method (e.g., KOH prep, culture)
Common pitfalls to avoid
Coding Candida infection without specifying the affected anatomical site (e.g., oral, skin, vaginal) leads to coding errors and claim denials. Proper documentation is crucial for accurate coding.
Lack of sufficient clinical evidence to support the Candida infection diagnosis can cause coding and billing inaccuracies. CDI specialists should query physicians for clarification.
Coding Candida based on symptoms alone without confirmatory lab tests or diagnostic procedures poses audit risks. Accurate diagnosis is essential for appropriate coding.
Best-practice tips
- 01ICD-10 B37 Candidiasis: Confirm species for accurate coding.
- 02Document lesion site, type (oral, skin), and severity for CDI.
- 03Screen for risk factors: diabetes, antibiotics, immunosuppression.
- 04Optimize antifungal Rx choice per site, species, drug resistance.
- 05Patient education: Hygiene, medication adherence, follow-up care.
Step-by-step checklist
- 1
Confirm patient symptoms (itching, burning, discharge)
- 2
Check affected area (skin, mouth, genitals, etc.)
- 3
Consider patient risk factors (diabetes, antibiotics)
- 4
Perform appropriate diagnostic tests (KOH, culture)
- 5
Document diagnosis with ICD-10 code (B37.x)
Ready-to-paste narrative
Patient presents with symptoms suggestive of a Candida infection (Candidiasis, yeast infection, thrush). The patient's chief complaint includes [specific patient complaint, e.g., oral thrush, vaginal itching, diaper rash, skin rash]. Physical examination reveals [objective findings, e.g., white plaques on the tongue, erythema and edema of the affected area, satellite lesions]. The patient's medical history includes [relevant medical history, e.g., diabetes, recent antibiotic use, immunosuppression, HIV]. Differential diagnoses considered include [alternative diagnoses, e.g., bacterial vaginosis, contact dermatitis, seborrheic dermatitis]. Based on the clinical presentation and findings, the diagnosis of Candida infection is made. Treatment plan includes [pharmacological and non-pharmacological interventions, e.g., topical antifungal cream such as clotrimazole or miconazole, oral fluconazole, nystatin suspension, improved hygiene practices]. Patient education provided regarding medication administration, potential side effects, and preventive measures. Follow-up appointment scheduled in [timeframe] to assess treatment response and resolution of symptoms. ICD-10 code [relevant ICD-10 code, e.g., B37.8, B37.9] is assigned for billing and coding purposes. Patient advised to contact the clinic if symptoms worsen or do not improve with treatment.
Common questions and answers
What are the most effective diagnostic tests for differentiating various types of Candida infections in clinical practice?+
Accurately diagnosing specific Candida species is crucial for targeted antifungal therapy. While culture remains the gold standard, it can be time-consuming. Rapid diagnostic tests like PCR and MALDI-TOF offer faster species identification and are particularly useful in critically ill patients. For mucosal infections, microscopic examination with KOH preparation can provide a rapid presumptive diagnosis. In disseminated candidiasis, blood cultures are essential, although sensitivity can be variable. Consider implementing antifungal stewardship programs to guide appropriate diagnostic testing and treatment based on the suspected site of infection and patient risk factors. Explore how these diagnostic tools can be integrated into your clinical workflow for improved patient outcomes.
How do I manage recurrent vulvovaginal candidiasis (RVVC) in patients who have failed standard antifungal treatments, considering both conventional and emerging therapies?+
Recurrent vulvovaginal candidiasis (RVVC), defined as four or more episodes per year, can significantly impact a patient's quality of life. Beyond confirming the diagnosis and ruling out other conditions, managing RVVC requires a multi-pronged approach. This includes optimizing long-term maintenance antifungal therapy, typically with fluconazole or topical azoles. For refractory cases, consider exploring emerging therapies like amphotericin B vaginal suppositories or investigating underlying predisposing factors such as uncontrolled diabetes or immunodeficiency. Non-pharmacological strategies, including probiotic use and dietary modifications, may also provide benefit. Learn more about the latest guidelines for managing RVVC to provide comprehensive care for your patients.
What are the key considerations for antifungal prophylaxis and empiric therapy in high-risk, non-neutropenic patients, such as those in the ICU with invasive Candida colonization?+
Invasive candidiasis poses a serious threat to critically ill, non-neutropenic patients. While antifungal prophylaxis is not universally recommended, it should be considered for high-risk individuals, such as those with invasive Candida colonization, severe abdominal surgery, or prolonged use of broad-spectrum antibiotics. Empiric therapy should be guided by local epidemiology and risk factors, with echinocandins generally preferred as first-line agents due to their broad spectrum and safety profile. Early de-escalation to fluconazole is possible once species identification and susceptibility results are available. Consider implementing a Candida score to stratify risk and guide antifungal decisions in your ICU. Explore how antifungal stewardship programs can optimize the use of antifungal agents and minimize the emergence of resistance.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.